Beta Bionics (NASDAQ:BBNX) Research Coverage Started at Robert W. Baird

Robert W. Baird initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Thursday, Marketbeat.com reports. The brokerage issued a neutral rating and a $20.00 price objective on the stock.

Beta Bionics Stock Down 1.4 %

BBNX opened at $20.57 on Thursday. Beta Bionics has a fifty-two week low of $20.57 and a fifty-two week high of $24.50.

Insider Buying and Selling

In other Beta Bionics news, insider Mike Mensinger purchased 33,350 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the purchase, the insider now owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.